Evidence map›Paper›PMID 36457575›Full record

ReviewFrontiers in medicine2022

Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.

Peter M Anderson, Vivek Subbiah, Matteo M Trucco

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Peter M AndersonDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, Cleveland Clinic Children's Hospital, Pediatric Institute, Cleveland Clinic, Cleveland, OH, United States.
Vivek SubbiahInvestigational Cancer Therapeutics, Cancer Medicine, Clinical Center for Targeted Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Matteo M TruccoDepartment of Pediatric Hematology, Oncology and Bone Marrow Transplant, Cleveland Clinic Children's Hospital, Pediatric Institute, Cleveland Clinic, Cleveland, OH, United States.
Cleveland Clinic · USTarget (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is a high-grade sarcoma characterized by osteoid formation, nearly universal expression of IGF1R and with a subset expressing HER-2. These qualities provide opportunities for the use of the alpha particle-emitting isotopes to provide targeted radiation therapy

Indexed as

bone metastasesdenosumabIGF1R antibody FPI-1434-225Aclung metastasesosteoblastic metastasesosteosarcomaradiosensitization

Identifiers

PMID36457575
PMCPMC9705365
OpenAlexW4309212466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.